Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19190143 | 0.89 | ADORA2A (0.58) | ADORA2AADORA2BADORA3 | |
| SCHEMBL13964740 | 0.89 | ADORA2A (0.58) | ADORA2AADORA2BADORA3 | |
| SCHEMBL13974841 | 0.89 | ADORA2A (0.58) | ADORA2AADORA2BADORA3 | |
| SCHEMBL26435554 | 0.89 | ADORA3 (0.54) | P2RY12ADORA1BMPR1BADORA2AADORA2B | |
| SCHEMBL13964749 | 0.89 | ADORA2A (0.58) | ADORA2AADORA2BADORA3 | |
| SCHEMBL25496571 | 0.88 | ADORA3 (0.59) | P2RY12ADORA1BMPR1BADORA2AADORA2B | |
| SCHEMBL26653466 | 0.88 | ADORA3 (0.59) | P2RY12ADORA1BMPR1BADORA2AADORA2B | |
| SCHEMBL21625242 | 0.87 | LMNA (0.60) | ADORA1ADORA2AADORA2BADORA3ALDH1A1 | |
| SCHEMBL18521420 | 0.87 | LMNA (0.60) | ADORA1ADORA2AADORA2BADORA3ALDH1A1 | |
| SCHEMBL21063207 | 0.87 | LMNA (0.60) | ADORA1ADORA2AADORA2BADORA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621624-B1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3621624-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | Merck Sharp & Dohme Corp. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | US | disclosed |
| WO-2018208667-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062798-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | P2RY12 360/4885ADORA1 36/4885BMPR1B 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.